All Posts

Human papillomavirus positive (HPV+) oropharyngeal cancer has become a distinct clinical entity with better prognosis than HPV-negative cases. Despite this, radiation therapy (RT) dosing has largely remained uniform, applying a “one-size-fits-all” approach that may not serve all patients equally well. Recently, a commentary published in the Journal of Clinical Investigation by Dr. Sandip Rath and Dr. David S. Yu sheds light on a promising method called Genomic Adjusted Radia

Triple-negative breast cancer (TNBC) remains one of the most challenging breast cancer subtypes to treat due to its aggressive nature and lack of targeted therapies. Recent research by Shane Stecklein and colleagues offers promising insights into how the Radiosensitivity Index (RSI) can help classify TNBC tumors and predict their response to therapy. This analysis sheds light on the tumor immune environment and how it changes with treatment, opening doors to more personalized

Radiotherapy has long been a cornerstone in cancer treatment, yet its application often follows a one-size-fits-all approach. This standardization can limit effectiveness and increase side effects because tumors and patients vary widely in their response to radiation. The French Society for Radiation Oncology (SFRO) has recently taken a significant step toward changing this by endorsing two genomic tools—the Radiosensitivity Index (RSI) and the Genome-based Adjusted Radiation